Nyvepria®
ACTIVE PRINCIPLE:
Pegfilgrastim
INDICATION:
neutropenia
DATE:
08/01/2021
STATUS:
Authorized
Biosimilar medicine authorized by the AEMPS
ACTIVE PRINCIPLE:
Pegfilgrastim
INDICATION:
neutropenia
DATE:
08/01/2021
STATUS:
Authorized
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.